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Apigenin (API) is a phytocompound belonging to the subclass of flavones that can be found in both functional 
foods as well as medicinal plants.  Recent studies have assigned API antioxidant, anti-inflammatory, anti-
spasmodic, anti-viral, anti-thrombotic, anti-angiogenic and chemopreventive  potential in vitro on various cell 
lines and/or in experimental animal models. Apigenin-7-O-glucoside (API-7) is one of its main glycosides and can 
be commonly found in chamomile flowers, parsley, celery. The aim of this study was to evaluate the in vitro  anti-
proliferative and pro-apoptotic effects of API and its glycoside (apigenin-7-O-glucoside) against HeLa human 
cervical cancer cells. Results have shown that in the set experimental conditions both the aglycone as well as the 
heteroside  elicit  antiproliferative and pro-apoptotic potential against the screened cell line, the aglycone being 
more active than the heteroside. 
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During history natural products from medicinal plants have played a very important role in protection of human health. 
The latest studies on this field have exhaustively demonstrated that an impressive number of representatives of Plant 
Kingdom have therapeutically valuable metabolites; hence, natural products obtain extensive importance to be used for 
medicinal purposes [1, 2]. In the latest years renewed interest in drugs of natural origins can be clearly observed. The 
qualities that recommend such an approach relief on some main advantages compared to chemically synthesized molecules 
that include easy availability and low toxicity at recommended therapeutic doses. Moreover, the easy availability and the 
fact that plant extracts contain different types of phytochemicals which can act by synergy in order to prevent or cure human 
disease are other arguments that come to support this kind of approach [3].    
Flavonoids (2-phenyl-1, 4-benzopyrone) (C15H10O5) have a fifteen carbon skeleton chemical structure which contain two 
phenyl rings and a heterocyclic ring. Flavonoids can be classified into six subclasses based on their structural complexity: 
flavones (artichockes, oranges, lime, grapefruit); flavan-3-ols (goji berries, cranberries, red onion, radish, buckwheat); 
flavanols (apple, peach, pecan nuits, black berries, dark chocolate); anthocyanins (raspberries, strawberries, black currant, 
red cabbage); flavanones (red grapes, chicory,green pepper,lemons); and isoflavones (soybean) [4]. Flavonoids are widely 
distributed in many medicinal plants like buckwheat, Japanese acacia, celery, parsley, chamomile, common hawthorn, 
ginkgo biloba, soybean, corn, silver birch [5,6]. API, chemically know as 4', 5, 7-trihydroxyflavone, belongs to the flavone 
subclass of flavonoids. It is the aglycone of some naturally occurring glycosides like apigetrin (API-7), vitexin (apigenin-
7-C-glucoside) and isovitexin (apigenin-6-C-glucosid). Apigetrin, also known as cosmosiin is a natural phytocompounds 
with better solubility compared to API [7]. API and cosmosiin can be found in many kinds of fruits, vegetables and 
nutraceuticals, like  Apium graveolens L., Pimpinella anisum L., Chrysanthemum morifolium L., Origanum vulgare L., 
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There are numerous research evidences that API and its main glycoside, apigetrin have similar biological activities, the 
main differences being the intensity of the biological effects [8]. API has been shown to have strong therapeutic potential 
against a significant number of diseases [9]. Studies in the field have assigned API antioxidant, anti-inflammatory, anti-
spasmodic, anti-viral, anti-thrombotic, anti-angiogenic potential [10]. Different doses of API reduced oxidative damage, 
neuro-inflammation and microglial activation, events that led to neuroprotective role in Parkinson disease [11]. The flavone 
is a potent competitive inhibitor of CYP2C9 an enzyme responsible for metabolism of many pharmaceutical drugs in the 
body [12]. Studies on the topic have shown that apigetrin the conjugated form of API, has remarkable anti-spasmodic, anti-
carcinogenic, antioxidant, anti-inflammatory, and anti-carcinogenic properties [13]. 
Nowadays, cancer is one of the most frightening diseases, affecting people of all ages. It is caused by abnormal 
proliferation and differentiation of cells, and is regulated by tumorigenic factors. Anticancer treatments generally use 
compounds that target rapidly dividing cells. This treatment has a negative side effect because the normal cells like epithelial 
cells in the digestive system or the hair follicles are also affected [14]. There is a growing interest in developing natural 
compounds for cancer therapy. API and API-7 play an important role in cancer prevention by inducing proliferation and 
apoptosis in various cancer cell lines. Literature describes both studies that have determinates API potential in in vitro  cell 
cultures, whereas others in in vivo animal models. Experimental animal models employing the fallowing cell lines : breast 
cancer (MCF-7), colon cancer (Caco-2), lung cancer (B16-BL6 murine melanoma cells), pancreatic cancer (PaCC), 
melanoma cancer (A375), hepatocellular carcinoma (HCC) were designed in order to evaluate the chemopreventive property 
of this phytocompound [15-19].An increased number of studies assign the cancer preventive effect of API to its anti-
inflammatory and antioxidant properties [20]. Studies on the topic have shown that in vitro it has antiproliferative and/or 
pro-apoptotic role against various cancer cell lines including: prostate cancer (PC-3 and DU145), hematologic cancer (HL-
60), ovarian cancer (HO-8910PM), liver cancer (HeLa), lung cancer B16-BL6 murine melanoma cells) and breast cancer 
(MCF7). Human trials are only effectuated in the form of supplements [21- 23]. In a similar approach a research group have 
compared API with apigetrin and have found that the glycoside part of apigetrin does not have role in the induction of cell 
differentiation. In fact, apigetrin inhibited cancer cell growth but to a lower extent than API [24]. 
The aim of this study was to investigate in vitro  the anti-proliferative and pro-apoptotic effects of API and its glycoside 
(API-7) against HeLa human cervical cancer cells. 
 
Experimental part 
Materials and methods 
API and API-7 ≥99% (HPLC) were acquired from Sigma-Aldrich, Germany 
 
Cell culture and preparation 
The HeLa human cervical cancer cell line (ECACC, European Collection of Cell Cultures, Salisbury, UK) was cultured 
into Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco BRL, Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
heat-inactivated fetal calf serum (FCS; PromoCell, Heidelberg, Germany) and 1% penicillin/streptomycin mixture 
(Pen/Strep, 10,000 IU/mL; PromoCell, Heidelberg, Germany). Experiments were conducted when cells were in the near-
confluent phase of growth 
 
Evaluation of the antiproliferative activity 
The growth-inhibitory activity of API  and API-7  was tested by standard MTT dye uptake assay on HeLa human cervical 
cancer cell line as previously described [25]. Briefly HeLa cells were counted and plated at a number of 5000 cells/well into 
96-well plates and incubated with the fallowing concentrations of API , respectively API-7: 0.3 µM, 1 µM, 3 µM, 10 µM, 
30 µM for 72 h. Afterwards 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was 
added and incubation was performed for another 4 h. Dimethyl sulfoxide was used in order to dissolve the precipitated 
formazan crystals and the absorbance was spectrophotometrically measured at 545 nm. Wells with untreated cells , 
respectively dimethyl sulfoxide were utilized as control. 
 
Evaluation of the pro-apoptotoc activity 
For the evaluation of the pro-apoptotic activity API , respectively API-7 on  HeLa human cervical cancer cell line,   DAPI 
(4′,6-diamidino-2-phenylindole) nucleic acid staining as well as the double Annexin V-FITC staining were performed as 
previously described [26, 27]. Based on the evaluation of the antiproliferative activity experiments the chosen concentrations 
of tested agents were  10 µM and  30 µM.  Briley, for DAPI staining HeLa cells were cultured in a 6-well plate and stimulated 
with the chosen concentrations for 72 h. At the end of this time point cells were washed twice with ice-cold PBS. The next 
step was fixation in 4% paraformaldehyde in PBS for a period of 30 min. The fixation was followed by another wash in 
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PBS and afterwards permeabilization was induced for 30 min with 2% Triton X-100 (Sigma Aldrich).Cells were blocked 
afterwards for one hour with 30% FCS in 0.01% Triton X-100. The DAPI staining was realized in the dark for 15 minutes. 
Visualization of cancer cell nuclei was performed with the help of a fluorescence Olympus IX73 microscope equipped with 
an integrated DP74 camera (Olympus, Tokyo, Japan).Magnification was 40×. Representative pictures are presented 
Translocation of the phosphatidylserine residues of the HeLa human cervical cancer cell line, as well as alteration of cell 
membrane and nuclei was detected by Annexin V-FITC combined with a propidium iodide (PI) kit (Invitrogen, 
ThermoFisher, Vienna, Austria).The number of cells employed in this experiment was 106 and the staining steps fallowed  
manufacturer’s protocol indications. The cells were analyzed by flow cytometry on FACS Canto II (BD Biosciences, 
Heidelberg, Germany) using a FACS DIVA device. The experiment was repeated three times. Representative dot-plots are 
presented. 
 
Results and discussions 
Results show that both API, the aglycone as well  as the  API-7 heteroside present an important antiproliferative activity 
against HeLa human cervical cancer cell line. The calculated IC 50 values are 12.08 µM for API respectively 18.28 µM for 
API-7. As expected the aglycone is more active than its conjugated form, but  the conjugation element ,glucose does not 
significantly influence the antiproliferative activity. At the highest tested concentration, namely 30 µM an inhibition of 
proliferation of 81.91± 0.59 for API, respectively 63.97±2.26 for API-7 could be detected. Results that depict logarithmic 

















In order to primary evaluate also a possible apoptotic potential as a secondary  mechanism for the anti-cancer 
activity, DAPI staining , a well-known technique that stains cell nuclei in blue was performed. Incubation with this 
phytocompound led to a reduction in cell number, as it can be seen by decreased number of stained nuclei in a selected field. 
Also condensed nuclei as a sign of loss of membrane integrity, condensed chromate filaments or nuclear fragmentation 
















Fig. 1 Antiproliferative activity of API 
and API-7 against HeLa human cervical 
cancer cell line 
 
Fig. 2 DAPI staining of HeLa human 
cervical cancer cell line after 
incubation with  API and API-7  
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The Annexin V-PI double staining show that HeLa human cervical cancer cells suffer phenomena of early apoptosis, 
late apoptosis and as well , in a low percentage necrosis. The number of total apoptotic events is linear  with the concentration 
, API being more active than API-7. The most frequent recorded phenomena were the early apoptotic ones. The average 
value of viable cells fallowing incubation with API -10 µM is 79±2;  API -7-10 µM is 84 ±3; API -30 is 67.5±2.5 µM   and  


















Over time, API has gained much popularity due to low toxicity on normal cells compared to cancer cells, this compound 
proved to possess chemopreventive and therapeutic potential against some variety of cell lines [28]. 
Human cervical cancer has two major histologic subtypes: squamous cell carcinoma (SCC) - SiHa and adenocarcinoma 
(AC) – HeLa. Patients with adenocarcinoma have a worse prognosis than patients with squamous cell carcinoma, requiring 
a specific therapeutic strategy to the cervical cancer subtype [29]. 
Our results demonstrated that both API, the aglycone as well as the API-7, the heteroside present a moderate 
antiproliferative and pro-apoptotic activity against HeLa human cervical cancer cell line but in a different manner,  the 
aglycone being more active than the heteroside. 
In a similar research line, Pei-Ming Yang et al. analyzed by the consecrated MTT assay the cytotoxicity of API using 
the human cervical cancer cell lines HeLa and SiHa in a dose range of 5-15 μM. Thus, in response to the treatment, results 
have shown that HeLa cells were more sensitive than SiHa cells, concluding that the anticancer effect of API may depend 
on the subtype of cancer of the cervix. A therapeutic approach that involves the combination of IFNγ with API has shown 
that API has a synergistic effect in combination with IFNγ. To analyze the combination effect of API and IFNγ, it was 
calculated the combination index (CI). The CI values in HeLa cells were lower than 1, thus it was observed that the 
combination of IFNγ with API has diminished  the cell viability in HeLa cells [29]. 
In a related approach the effects of API and API-7 on other cell lines have also been studied. 
The group of Haihua Bai et al. evaluated the effects of API on MCF-7 human breast cancer cell lines and MCF-10A 
human normal mammary cells. Both viability as well as apoptosis had  a direct proportional dose-dependent and time 
relationship with API concentration. IC50 was 109.3 ± 3.7 μmol / L fallowing 24 h of incubation and 65.8 ± 4.3 μmol / L 
fallowing 24 h of incubation of MCF-7 cell lines. Results showed that API inhibits the growth of MCF-7 cells dose-
dependent, but without cytotoxic effects on normal breast cells. Cell apoptosis was determined by Annexin V-FITC-PI 
double staining. It was observed that 24 h exposure to 100 μmol / L API induced a significant augmentation of late apoptosic 
and necrotic events of MCF-7 cells (from 1.6% to 17.2%). Decreasing the dose to 80 μmol / L, the ratio of early apoptosis 
in MCF-7 cells changed (from 1.1% to 18.6%.). The study concluded that API can induce both apoptosis as well as necrosis 
in MCF-7 cancer cells [30]. 
Nouha Nasr Bouzaiene et al. have shown that incubation of B16F10 mouse melanoma cells with apigenin-7-glucoside 
in the dose range [10-50 μM ] using as time points 24 and 48 h inhibited cell proliferation in a dose-dependent manner. To 
explicate the death mechanism of B16F10 cells induced by apigenin-7-glucoside, it was examined whether API-7 can induce 
apoptosis by observing morphological changes, these being analyzed and quantified by fluorescent microscopy. At the 
highest concentrations, it was discovered that the percentage of apoptotic cells increased from 5% (control) to 43% in case 
of cells incubated for 48 h with API-7 [31]. 
Fig.3  Annexin V-PI staining of 
HeLa human cervical cancer cell 
line after incubation with  API 
and API-7  
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In the study designed by Whasun Lim et al., the viability of two types of choriocarcinoma cells (JAR and JEG3) was  
examined after  incubation with API at doses of 0,5; 10; 20; 50 and 100 μM. Between concentrations of [10-100 μM], API 
reduced survival of JEG3 cells. The populations of apoptotic choriocarcinoma cells were estimated by annexin V and 
propidium iodide (PI) staining. The percentage of apoptotic JAR and JEG3 cells increased following incubation with 20 
μM API with the following percentages: 30% for JAR cells and 50% for JEG3 cells [32]. 
In a similar approach, Shuhua Shan et al. showed a reduction in the survival rate of three colon cancer cell lines (HCT116, 
HT29 and DLD1) following treatment with API. The IC50   values against HCT116, HT29, and DLD1 cells were 27.9±2.45, 
48.2±3.01 and 89.5±4.89 µM [33]. 
As for an in vivo approach Hui-Hui Cao et al. demonstrated the anti-metastatic effect of API in an animal model of 
melanoma that involved the injection of B16F10 melanoma cells into syngenic C57BL / 6 mice. Some of these species were 
treated with API (150 mg / kg) and others with vehicle (0.5% CMC-Na solution). The metastatic nodules in case of  API 
treated mice was significantly reduced compared to those treated with vehicle [34]. 
 
Conclusions 
In the set experimental conditions, API as well as  API-7 presents in vitro antiproliferative and pro-apoptotic potential 
against HeLa human cervical cancer cell line, the aglycone being more active than the heteroside. 
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